>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 . Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
After reconstitution, this product is stable after storage at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H2) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) with a linear range of 0.2-3 ng/mL (QC tested).
Detection of SARS-CoV-2 S protein RBD by Sandwich ELISA Assay.
Immobilized Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) at 2 μg/mL (100 μL/well) can bind S protein RBD. And then add Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M130) at 1:5000. Detection was performed using HRP-conjugated streptavidin with sensitivity of 25 pg/mL (Routinely tested).
Anti-SARS-CoV-2 Spike RBD Neutralizing antibody (Cat.No. S1N-M122) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD: ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2 mutant and treated with the neutralizing antibody at increasing concentration. Percent inhibition is calculated based on the OD value.
Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) with an affinity constant of 0.375 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.